Ginkgo Bioworks and Merck have collaborated to improve the production of biologics.
Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields.
“We’re thrilled to leverage our platform to improve the production of biologics in collaboration with Merck,” said Jason Kelly, CEO and Co-Founder of Ginkgo Bioworks. “In particular, we will utilise some of our unique capabilities, such as automated protocols to do predictive ultra high-throughput multiplexed screening, product characterisation and process optimisation. It’s exciting for our team to drive impactful and technically innovative work, and to do so shoulder-to-shoulder with our counterparts at Merck.”
“At Merck, we are always seeking new and innovative ways to optimise process efficiency while maintaining product integrity,” said Dr Michael Kress, Senior Vice President, Development Sciences and Clinical Supply, Merck Research Laboratories.
